Boehringer Ingelheim Micardis
BI disseminated promotional information for Micardis (telmisartan) prior to submitting the materials to FDA for approval, in violation of post-marketing requirements, FDA says in an April 16 letter. In addition, several of the materials that were submitted late include misleading representations of the angiotesin II receptor blocker's efficacy and safety, the letter notes. Use of the header "the time is right for an ARB like Micardis" over safety and efficacy information "implies that other available [ARBs] do not possess similar characteristics, and that Micardis therapy is superior, when compared to them," FDA says. The agency also notes "misleading use of pharmacokinetic data" in BI's presentation of the claim "24-hour half-life for once-daily dosing," which, the agency says, "implies that the duration of clinical effectiveness is due to Micardis' half-life duration"
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth